Close

How You Made 818% on This Biotech Blockbuster Buyout

Back in early April 2012, in a special report called “The Biotech Buyout Binge,” I explained that we would start seeing a slew of takeovers – engineered by cash-rich biopharmaceutical firms desperate to replace blockbusters that were losing patent protection.

We were right about the so-called “patent cliff.” According to a recent Towers Watson study, there have been about 300 merger-and-acquisition (M&A) deals in the biopharma sector alone.